ES2238941T1 - Solvato de hemitartrato de zolpidem. - Google Patents
Solvato de hemitartrato de zolpidem.Info
- Publication number
- ES2238941T1 ES2238941T1 ES04010435T ES04010435T ES2238941T1 ES 2238941 T1 ES2238941 T1 ES 2238941T1 ES 04010435 T ES04010435 T ES 04010435T ES 04010435 T ES04010435 T ES 04010435T ES 2238941 T1 ES2238941 T1 ES 2238941T1
- Authority
- ES
- Spain
- Prior art keywords
- zolpidem hemitartrate
- hydrate
- solvate
- zolpidem
- hemitartrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VXRDAMSNTXUHFX-CEAXSRTFSA-N zolpidem tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 VXRDAMSNTXUHFX-CEAXSRTFSA-N 0.000 title claims abstract 26
- 239000012453 solvate Substances 0.000 title claims abstract 12
- 150000004683 dihydrates Chemical class 0.000 claims abstract 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000004682 monohydrates Chemical class 0.000 claims abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 2
- 150000004685 tetrahydrates Chemical class 0.000 claims 2
- 150000004684 trihydrates Chemical class 0.000 claims 2
- VDGOTZAKEQIVOP-UHFFFAOYSA-N C(CCC)O.C(C(O)C(O)C(=O)O)(=O)O.C(CCC)O Chemical compound C(CCC)O.C(C(O)C(O)C(=O)O)(=O)O.C(CCC)O VDGOTZAKEQIVOP-UHFFFAOYSA-N 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 claims 1
- 229960001475 zolpidem Drugs 0.000 claims 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 1
- SRDBTVMAHGZQGD-UHFFFAOYSA-N O.O.O.O.O.O.O Chemical compound O.O.O.O.O.O.O SRDBTVMAHGZQGD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Amplifiers (AREA)
- Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
- Suspension Of Electric Lines Or Cables (AREA)
- Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Solvato de hemitartrato de zolpidem. El solvato es un hidrato. El hidrato es un monohidrato, dihidrato. trihidrato.tetrahidrato. El solvato se selecciona de entre el grupo constituido por isopropanol de hemitartrato de zolpidem, butanol de hemitartrato de zolpidem, acetato de etilo de hemitartrato de zolpidem y acetona de hemitartrato de zolpidem.
Claims (24)
1. Solvato de hemitartrato de zolpidem.
2. Solvato de hemitartrato de zolpidem según la
reivindicación 1, en el que solvato es un hidrato.
3. Hidrato según la reivindicación 2, en el que
el hidrato es un monohidrato.
4. Hidrato según la reivindicación 2, en el que
el hidrato es un dihidrato.
5. Hidrato según la reivindicación 2, en el que
el hidrato es un trihidrato.
6. Hidrato según la reivindicación 2, en el que
el hidrato es un tetrahidrato.
7. Hidrato según la reivindicación 2, en el que
el hidrato es un hidrato 2/3.
8. Hidrato según la reivindicación 2 ó 3, en el
que el hemitartrato de zolpidem es un monohidrato de Forma D.
9. Hidrato según la reivindicación 8, en el que
el hemitartrato de zolpidem es una Forma D, en el que el contenido
de agua está comprendido entre aproximadamente 2,3% y
aproximadamente 2,7% en peso.
10. Solvato según la reivindicación 1, en el que
el hemitartrato de zolpidem es un hemietanolato de Forma D.
11. Solvato según la reivindicación 10, en el que
el solvato se selecciona de entre el grupo constituido por
isopropanol de hemitartrato de zolpidem, butanol de hemitartrato de
zolpidem, acetato de etilo de hemitartrato de zolpidem y acetona de
hemitartrato de zolpidem.
12. Hidrato según la reivindicación 2 ó 4, en el
que el hemitartrato de zolpidem es un dihidrato de Forma E.
13. Hidrato según la reivindicación 2 ó 5, en el
que el hemitartrato de zolpidem es un trihidrato de Forma E.
14. Hidrato según la reivindicación 2 ó 6, en el
que el hemitartrato de zolpidem es un tetrahidrato de Forma E.
15. Hidrato según la reivindicación 2, en el que
el hemitartrato de zolpidem es la Forma E y el contenido en agua
está comprendido entre aproximadamente 5,0% y aproximadamente 8,5%
en peso.
16. Solvato según la reivindicación 1, en el que
el hemitartrato de zolpidem es un metalonato de Forma F.
17. Forma F del hemitartrato de zolpidem según la
reivindicación 16, en el que el contenido de metanol es de
aproximadamente 5,5% en peso.
18. Solvato según la reivindicación 1, en el que
el hemitartrato de zolpidem es un dihidrato de Forma G.
19. Hidrato según la reivindicación 2 ó 4, en el
que el hemitartrato de zolpidem es un dihidrato de Forma L.
20. Hidrato según la reivindicación 19, en el que
el contenido de agua es de aproximadamente 4,3% en peso.
21. Hemitartrato de zolpidem según cualquiera de
las reivindicaciones anteriores, que presenta unas partículas con
un tamaño de hasta 200 micrones tal como se mide mediante
difracción láser.
22. Hemitartrato de zolpidem según la
reivindicación 21, que presenta unas partículas con un tamaño de
hasta aproximadamente 50 micrones.
23. Composición farmacéutica que comprende una
cantidad terapéuticamente efectiva de hemitartrato de zolpidem según
cualquiera de las reivindicaciones anteriores y un vehículo
farmacéuticamente aceptable.
24. Utilización de un hemitartrato de zolpidem
según cualquiera de las reivindicaciones anteriores, en la
preparación de un medicamento destinado al tratamiento del
insomnio.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19929800P | 2000-04-24 | 2000-04-24 | |
| US199298P | 2000-04-24 | ||
| US20602500P | 2000-05-22 | 2000-05-22 | |
| US206025P | 2000-05-22 | ||
| US22536400P | 2000-08-14 | 2000-08-14 | |
| US225364P | 2000-08-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2238941T1 true ES2238941T1 (es) | 2005-09-16 |
| ES2238941T3 ES2238941T3 (es) | 2007-04-01 |
Family
ID=27394001
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04010651T Expired - Lifetime ES2239558T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem micronizado. |
| ES04010435T Expired - Lifetime ES2238941T3 (es) | 2000-04-24 | 2001-04-24 | Solvato de hemitartrato de zolpidem. |
| ES01930705T Expired - Lifetime ES2248321T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem. |
| ES05001922T Expired - Lifetime ES2277301T3 (es) | 2000-04-24 | 2001-04-24 | Solvato de hemitartrato de zolpidem. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04010651T Expired - Lifetime ES2239558T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem micronizado. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01930705T Expired - Lifetime ES2248321T3 (es) | 2000-04-24 | 2001-04-24 | Hemitartrato de zolpidem. |
| ES05001922T Expired - Lifetime ES2277301T3 (es) | 2000-04-24 | 2001-04-24 | Solvato de hemitartrato de zolpidem. |
Country Status (21)
| Country | Link |
|---|---|
| US (8) | US20020077332A1 (es) |
| EP (1) | EP1292304B1 (es) |
| JP (3) | JP2003531173A (es) |
| KR (1) | KR20030069796A (es) |
| AT (4) | ATE338550T1 (es) |
| AU (2) | AU2001257213B2 (es) |
| CA (1) | CA2406982A1 (es) |
| CZ (1) | CZ20023775A3 (es) |
| DE (7) | DE20122435U1 (es) |
| DK (1) | DK1292304T3 (es) |
| ES (4) | ES2239558T3 (es) |
| HR (1) | HRP20020909A2 (es) |
| HU (1) | HUP0300701A2 (es) |
| IL (1) | IL152411A0 (es) |
| NZ (1) | NZ522015A (es) |
| PL (1) | PL358548A1 (es) |
| PT (3) | PT1473036E (es) |
| SE (1) | SE5292304T3 (es) |
| SK (1) | SK16372002A3 (es) |
| WO (1) | WO2001080857A1 (es) |
| YU (1) | YU79402A (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001284322A1 (en) | 2000-08-29 | 2002-03-13 | Ranbaxy Laboratories Limited | Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide, a key intermediate of zolpidem |
| US6869970B2 (en) | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
| DK1575952T3 (da) | 2002-12-18 | 2009-05-25 | Mallinckrodt Inc | Syntese af heteroarylacetamider |
| WO2004087703A1 (en) * | 2003-03-12 | 2004-10-14 | Sun Pharmaceutical Industries Limited | Process for the preparation of n,n,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide |
| WO2005010002A1 (en) * | 2003-07-31 | 2005-02-03 | Ranbaxy Laboratories Limited | Process for the synthesis of zolpidem |
| US7658945B2 (en) * | 2004-02-17 | 2010-02-09 | Transcept Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
| WO2006008636A2 (en) * | 2004-07-16 | 2006-01-26 | Ranbaxy Laboratories Limited | Processes for the preparation of zolpidem and its hemitartrate |
| US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
| US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
| NZ563979A (en) * | 2005-05-25 | 2011-02-25 | Transcept Pharmaceuticals Inc | Solid compositions and methods for treating middle-of-the night insomnia |
| CA2617975A1 (en) * | 2005-08-19 | 2007-03-01 | Aventis Pharmaceuticals Inc. | Combination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof |
| ES2336142T3 (es) * | 2005-08-19 | 2010-04-08 | Aventis Pharmaceuticals Inc. | Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo. |
| AU2006297475A1 (en) * | 2005-10-03 | 2007-04-12 | Mallinckrodt Inc. | Process for preparing zolpidem hemitartrate and tartrate polymorphs |
| AU2006303000A1 (en) * | 2005-10-17 | 2007-04-26 | Mallinckrodt Inc. | Polymorph transformation of Zolpidem in tablet matrix |
| US20070098788A1 (en) * | 2005-10-28 | 2007-05-03 | Gore Subhash P | Non-benzodiazepine hypnotic compositions |
| ES2348829T3 (es) | 2006-03-31 | 2010-12-15 | Janssen Pharmaceutica Nv | Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina. |
| US20080132535A1 (en) * | 2006-11-30 | 2008-06-05 | Transcept Pharmaceuticals, Inc. | Stabilized Zolpidem Pharmaceutical Compositions |
| US20080145425A1 (en) * | 2006-12-15 | 2008-06-19 | Pliva Research & Development Limited | Pharmaceutical composition of zolpidem |
| TW201018668A (en) * | 2008-06-30 | 2010-05-16 | Janssen Pharmaceutica Nv | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
| US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
| CA2781676C (en) | 2009-11-27 | 2020-05-05 | Genzyme Corporation | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| WO2011115069A1 (ja) * | 2010-03-19 | 2011-09-22 | 第一三共株式会社 | 結晶の網羅的探索 |
| BR112015021463A8 (pt) | 2013-03-06 | 2019-11-19 | Janssen Pharmaceutica Nv | moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4,seu uso e composição faramacêutica |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| FR2408345A1 (fr) * | 1976-11-30 | 1979-06-08 | Besins Jean Louis | Nouvelle composition a action anti-conceptionnelle |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| IT1130924B (it) * | 1980-03-06 | 1986-06-18 | Secifarma Spa | Procedimento per la preparazione di spironolattone micronizzato |
| DE3018940A1 (de) * | 1980-05-17 | 1981-11-26 | Hoechst Ag, 6000 Frankfurt | Verwendung eines vinylchlorid-pfropf-copolymerisates in der plastisolverarbeitung |
| FR2492382A1 (fr) * | 1980-10-22 | 1982-04-23 | Synthelabo | Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique |
| FR2525601A1 (fr) * | 1982-04-21 | 1983-10-28 | Synthelabo | Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| US4675323A (en) * | 1985-08-06 | 1987-06-23 | Synthelabo | Imidazo(1,2-a)quinoline derivatives useful as anxiolytic agents |
| SE457326B (sv) * | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa |
| FR2600650B1 (fr) * | 1986-06-27 | 1988-09-09 | Synthelabo | Procede de preparation d'imidazopyridines et composes intermediaires |
| FR2606410B1 (fr) * | 1986-11-07 | 1989-02-24 | Synthelabo | Imidazopyridines, leur preparation et leur application en therapeutique |
| DE3865073D1 (de) * | 1987-03-27 | 1991-10-31 | Synthelabo | Imidazopyridinderivate, ihre herstellung und therapeutische verwendung. |
| US5271944A (en) * | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
| IT1276522B1 (it) * | 1995-04-07 | 1997-10-31 | Elena Benincasa | Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei |
| ES2195510T3 (es) * | 1999-03-25 | 2003-12-01 | Synthon Bv | Derivados de imidazopiridina y procedimiento para prepararlos. |
| ES2240074T3 (es) * | 1999-03-25 | 2005-10-16 | Synthon B.V. | Sales de zolpidem. |
| AU6474200A (en) * | 1999-12-13 | 2001-06-18 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a pyridinemethanol compound |
-
2001
- 2001-04-24 PT PT04010435T patent/PT1473036E/pt unknown
- 2001-04-24 ES ES04010651T patent/ES2239558T3/es not_active Expired - Lifetime
- 2001-04-24 SE SE01930705T patent/SE5292304T3/xx unknown
- 2001-04-24 DE DE20122435U patent/DE20122435U1/de not_active Expired - Lifetime
- 2001-04-24 DE DE04010435T patent/DE04010435T1/de active Pending
- 2001-04-24 ES ES04010435T patent/ES2238941T3/es not_active Expired - Lifetime
- 2001-04-24 NZ NZ522015A patent/NZ522015A/en unknown
- 2001-04-24 EP EP01930705A patent/EP1292304B1/en not_active Revoked
- 2001-04-24 AT AT04010651T patent/ATE338550T1/de not_active IP Right Cessation
- 2001-04-24 DE DE04010651T patent/DE04010651T1/de active Pending
- 2001-04-24 PT PT04010651T patent/PT1475093E/pt unknown
- 2001-04-24 PT PT05001922T patent/PT1541146E/pt unknown
- 2001-04-24 AU AU2001257213A patent/AU2001257213B2/en not_active Ceased
- 2001-04-24 CZ CZ20023775A patent/CZ20023775A3/cs unknown
- 2001-04-24 AT AT01930705T patent/ATE308324T1/de not_active IP Right Cessation
- 2001-04-24 IL IL15241101A patent/IL152411A0/xx unknown
- 2001-04-24 DE DE60122216T patent/DE60122216T2/de not_active Expired - Fee Related
- 2001-04-24 JP JP2001577956A patent/JP2003531173A/ja not_active Withdrawn
- 2001-04-24 HU HU0300701A patent/HUP0300701A2/hu unknown
- 2001-04-24 SK SK1637-2002A patent/SK16372002A3/sk not_active Application Discontinuation
- 2001-04-24 AT AT05001922T patent/ATE348613T1/de not_active IP Right Cessation
- 2001-04-24 US US09/841,025 patent/US20020077332A1/en not_active Abandoned
- 2001-04-24 CA CA002406982A patent/CA2406982A1/en not_active Abandoned
- 2001-04-24 YU YU79402A patent/YU79402A/sh unknown
- 2001-04-24 KR KR1020027014220A patent/KR20030069796A/ko not_active Application Discontinuation
- 2001-04-24 AU AU5721301A patent/AU5721301A/xx active Pending
- 2001-04-24 DK DK01930705T patent/DK1292304T3/da active
- 2001-04-24 ES ES01930705T patent/ES2248321T3/es not_active Expired - Lifetime
- 2001-04-24 PL PL01358548A patent/PL358548A1/xx not_active Application Discontinuation
- 2001-04-24 DE DE60114617T patent/DE60114617T2/de not_active Expired - Fee Related
- 2001-04-24 WO PCT/US2001/013175 patent/WO2001080857A1/en active IP Right Grant
- 2001-04-24 ES ES05001922T patent/ES2277301T3/es not_active Expired - Lifetime
- 2001-04-24 DE DE60122944T patent/DE60122944T2/de not_active Expired - Fee Related
- 2001-04-24 AT AT04010435T patent/ATE335481T1/de not_active IP Right Cessation
- 2001-04-24 DE DE60125429T patent/DE60125429T2/de not_active Expired - Fee Related
-
2002
- 2002-11-15 HR HR20020909A patent/HRP20020909A2/hr not_active Application Discontinuation
-
2004
- 2004-05-24 US US10/852,912 patent/US20040214858A1/en not_active Abandoned
- 2004-05-24 US US10/853,640 patent/US20040214859A1/en not_active Abandoned
- 2004-05-24 US US10/853,345 patent/US20040220213A1/en not_active Abandoned
- 2004-05-24 US US10/853,033 patent/US20040220211A1/en not_active Abandoned
- 2004-05-24 US US10/853,338 patent/US20040220212A1/en not_active Abandoned
- 2004-05-24 US US10/853,031 patent/US20040220210A1/en not_active Abandoned
-
2006
- 2006-02-09 JP JP2006033099A patent/JP2006137778A/ja active Pending
- 2006-06-27 JP JP2006177160A patent/JP2006249105A/ja active Pending
- 2006-10-25 US US11/588,122 patent/US20070037843A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2238941T1 (es) | Solvato de hemitartrato de zolpidem. | |
| ES2582646T3 (es) | Formulación de comprimido recubierto y método | |
| ES2665539T3 (es) | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 | |
| ES2377066T3 (es) | Composición terapéutica que contiene al menos un derivado de la pirrobenzodiacepina y la fludarabina | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
| AR049142A1 (es) | Composiciones para recubrimientos de azucar,composiciones recubiertas y metodos para la fabricacion de los mismos | |
| AR120676A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
| AR055669A1 (es) | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. | |
| PE20020307A1 (es) | Forma de dosificacion de farmaco activada por hidrogel | |
| PL2018379T3 (pl) | Sole skopiny oraz ich zastosowanie w sposobach wytwarzania N-demetylo-tiotropium i bromku tiotropium | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
| AR074739A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
| AR054806A1 (es) | Formulaciones de estrogenos conjugados y bazedoxifeno | |
| CO6150122A2 (es) | Comprimidos pediatricos de capecitabina | |
| ECSP066693A (es) | Derivados de bencimidazol | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| MX2007001267A (es) | Derivados de naftiridinas 2,8-disustituidas. | |
| SI1608346T1 (sl) | Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabe | |
| HUP0203844A2 (hu) | Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása | |
| JP2004505036A5 (es) | ||
| NZ516290A (en) | Substituted phenoxyacetic acids | |
| ATE303137T1 (de) | Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit |